- Home
- HURA vs PLRX Comparison
HURA vs PLRX Comparison
Compare HURA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | PLRX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 79.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HURA | PLRX |
|---|---|---|
| Price | $2.12 | $1.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $10.00 | $2.67 |
| AVG Volume (30 Days) | ★ 899.6K | 609.4K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.09 |
| 52 Week High | $4.41 | $1.95 |
Technical Indicators
Market Signals| Indicator | HURA | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.36 | 57.06 |
| Support Level | $1.56 | $1.12 |
| Resistance Level | $2.16 | $1.36 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 85.25 | 58.54 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.